MEGALOTECT

This brand name is authorized in Hong Kong, Israel, Netherlands, Poland, Singapore, Turkey, South Africa

Active ingredients

The drug MEGALOTECT contains one active pharmaceutical ingredient (API):

1 Immunoglobulin human anti-cytomegalo-virus UNII 129L90A25N - HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN

Cytomegalovirus immunoglobulin is used as a CMV-specific polyclonal immunoglobulin preparation that binds to CMV surface antigens thereby neutralizing the potential of CMV from entering host cells and presenting the CMV particle for phagocytosis. Furthermore, cytomegalovirus immunoglobulin can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses. Read about Cytomegalovirus immunoglobulin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BB09	Cytomegalovirus immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 66874
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6893
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 134457, 134465
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100406130
Country: SG	Health Sciences Authority	Identifier(s): 14452P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699535980622, 8699535980639
Country: ZA	Health Products Regulatory Authority	Identifier(s): 28/30.2/0110